The 2023 Endpoints 11; Regeneron’s gene editing ambitions; GSK’s research revamp; Ripple effect of Dana-Farber, Brigham breakup; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
While an Endpoints crew assembled in Boston for Endpoints 11, one of our biggest projects of the year, the rest of the team held down the fort and delivered excellent coverage from other corners of the world. We take a look at Regeneron’s bet on gene editing delivery, GSK’s research revamp, the impact of the breakup between Dana-Farber and Brigham and Women’s Hospital, notable startup launches, and more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.